Cytek Biosciences Reports Second Quarter 2026 Financial Results
Cytek reported Q2 revenue of $48.1 million, up 6% year-over-year, driven by instrument growth in the U.S. and China and a one-time tariff refund that boosted gross margins to 59%. Despite the revenue increase, the net loss widened significantly to $12.2 million from $5.6 million in the prior year, and adjusted EBITDA swung to a loss of $1.5 million.
Key figures
- Revenue
- 48140000
- Guidance
- FY2026 revenue $207 million to $212 million, raising midpoint by $1 million
- Revenue Yoy
- 6%
- Net loss
- 12200000
- Gross margin
- 59%
- Gross profit
- 28340000
- Recurring revenue
- 18500000
- Adjusted gross margin
- 61%
- Installed base instruments
- 3933
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.